Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial

<p><strong>Background:</strong> Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The <i>Plasmodium falciparum</i> Pfs25 protein (Pfs25) is the most clinically ad...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: de Graaf, H, Payne, RO, Taylor, I, Miura, K, Long, CA, Elias, SC, Zaric, M, Minassian, AM, Silk, SE, Li, L, Poulton, ID, Baker, M, Draper, SJ, Gbesemete, D, Brendish, NJ, Martins, F, Marini, A, Mekhaiel, D, Edwards, NJ, Roberts, R, Vekemans, J, Moyle, S, Faust, SN, Berrie, E, Lawrie, AM, Hill, F, Hill, AVS, Biswas, S
Formatua: Journal article
Hizkuntza:English
Argitaratua: Frontiers Media 2021

Antzeko izenburuak